| # | % | |||||
|---|---|---|---|---|---|---|
| 1 | ARRAY BIOPHARMA INC COM | 9,169,276 | 66,110,000 | 11.67% | ||
| 2 | CHEMOCENTRYX INC | 7,270,013 | 59,832,000 | 10.56% | ||
| 3 | BLUEPRINT MEDICINES CORP COM | 1,582,408 | 41,918,000 | 7.40% | ||
| 4 | FORWARD PHARMA A/S | 1,008,981 | 38,392,000 | 6.78% | ||
| 5 | CONCERT PHARMACEUTICALS INC COM | 2,521,452 | 37,544,000 | 6.63% | ||
| 6 | ONCOTHYREON INC COM N/C EFF 6/ | 9,754,178 | 36,481,000 | 6.44% | ||
| 7 | Exelexis | 38,239,000 | 34,009,000 | 6.00% | PRN | |
| 8 | LOXO ONCOLOGY INC COM | 1,615,081 | 29,120,000 | 5.14% | ||
| 9 | ONCOMED PHARMACEUTICALS INC | 1,264,715 | 28,456,000 | 5.02% | ||
| 10 | IRONWOOD PHARMACEUTICALS INC COM CL A | 2,171,108 | 26,184,000 | 4.62% | ||
| 11 | VITAE PHARMACEUTICALS INC | 1,604,615 | 23,106,000 | 4.08% | ||
| 12 | TOBIRA THERAPEUTICS INC | 1,175,233 | 20,273,000 | 3.58% | ||
| 13 | TARGACEPT INC | 6,655,128 | 18,568,000 | 3.28% | ||
| 14 | GTX INC | 10,772,306 | 15,835,000 | 2.79% | ||
| 15 | QLT INC | 3,737,446 | 15,436,000 | 2.72% | ||
| 16 | CYTOKINETICS INC | 2,106,989 | 14,159,000 | 2.50% | ||
| 17 | EXELIXIS INC | 2,766,152 | 10,401,000 | 1.84% | ||
| 18 | ArQule Inc | 6,430,708 | 10,289,000 | 1.82% | ||
| 19 | SEATTLE GENETICS INC | 200,000 | 9,680,000 | 1.71% | ||
| 20 | XENON PHARMACEUTICALS INC | 678,764 | 7,826,000 | 1.38% | ||
| 21 | FIVE PRIME THERAPEUTICS INC | 240,597 | 5,976,000 | 1.05% | ||
| 22 | ARRAY BIOPHARMA INC 3 06/01/2020 | 2,500,000 | 3,169,000 | 0.56% | PRN | |
| 23 | Catabasis Pharmaceuticals Inc | 225,000 | 2,747,000 | 0.48% | ||
| 24 | MAST THERAPEUTICS | 5,111,293 | 2,505,000 | 0.44% | ||
| 25 | Life Technologies Corp | 134,725 | 2,495,000 | 0.44% | ||
| 26 | OncoGenex Pharmaceuticals Inc | 1,020,108 | 2,377,000 | 0.42% | ||
| 27 | GLOBEIMMUNE INC | 678,400 | 1,771,000 | 0.31% | ||
| 28 | BIOTA PHARMACEUTIALS INC COM | 350,776 | 726,000 | 0.13% | ||
| 29 | ACHAOGEN INC COM | 106,700 | 643,000 | 0.11% | ||
| 30 | Aptose Biosciences Inc Com New | 105,429 | 538,000 | 0.09% |
Portfolio data is normalized using SEC Form 13F filings, including the Original 13F-HR (0000921895-15-002011, filed 2015.08.14).
From 2023-01-03 onward, the SEC requires values to be reported in nearest dollars. Earlier filings reported values in thousands; therefore, positions shown as $0 in older filings may represent actual values between $0–$999.
